Active, Not Recruiting ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) NCT04044859 Conditions Adnexal Diseases, Bronchial Neoplasms, Carcinoma, Bronchogenic, +54 more Locations Name of Institution: Orlando Health Cancer Institute — Orlando, Florida, United States Massachusetts General Hospital — Boston, Massachusetts, United States Washington University - School of Medicine — St Louis, Missouri, United States Memorial Sloan Kettering Cancer Center — New York, United States View all 17 locations View more locations Show fewer locations Loading locations... View Trial Details
